Abstract
Liver hepatocellular carcinoma (LIHC) is the second leading cause of cancer mortality worldwide. Although cancer driver genes identified so far have been considered to be saturated or nearly saturated, challenges remain in discovering novel genes underlying carcinogenesis due to significant tumor heterogeneity. Here, in a small cohort of hepatitis B virus (HBV)-associated LIHC, we investigated the transcriptional patterns of tumor-mutated alleles using both whole-exome and RNA sequencing data. A graph clustering of the transcribed tumor-mutated alleles characterized overlapped functional clusters, and thus prioritized potentially novel oncogenes. We validated the function of the potentially novel oncogenes in vitro and in vivo. We showed that a component of the retromer complex—the vacuolar protein sorting-associated protein 35 (VPS35)—promoted the proliferation of hepatoma cell through the PI3K/AKT signaling pathway. In VPS35-knockout hepatoma cells, a significantly reduced distribution of membrane fibroblast growth factor receptor 3 (FGFR3) demonstrated the effects of VPS35 on sorting and trafficking of transmembrane receptor. This study provides insight into the roles of the retromer complex on carcinogenesis and has important implications for the development of personalized therapeutic strategies for LIHC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Supplementary materials including tables and figures. Whole exome sequencing data for LIHC tumor and its paired cirrhotic tissues, and peripheral blood lymphocytes, as well as RNA sequencing data for LIHC tumor and its paired cirrhotic tissues have been submitted to the Sequence Read Archive (SRA) (https://submit.ncbi.nlm.nih.gov/) under the number SUB6779164. RNA sequencing data for parental and VPS35-KO SK-Hep1 cell lines have been submitted to the SRA under the number SUB6834808. The source code is available upon request. Supplementary information is available at Oncogene’s website.
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359–86.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9:138–41.
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62.
Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet. 2011;43:464–9.
Huang J, Deng Q, Wang Q, Li K-Y, Dai J-H, Li N, et al. Exome sequencing of hepatitis B virus associated hepatocellular carcinoma. Nat Genet. 2012;44:1117–21.
Sung W-K, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44:765–9.
Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23:1422–33.
Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology. 2013;58:1693–702.
Shibata T, Aburatani H. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol. 2014;11:340–9.
Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016;65:1031–42.
Creixell P, Reimand J, Haider S, Wu G, Shibata T, Vazquez M, et al. Pathway and network analysis of cancer genomes. Nat Methods. 2015;12:615–21.
Ding L, Wendl MC, McMichael JF, Raphael BJ. Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet. 2014;15:556–70.
Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327–41.e23.
Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173:371–85.e18.
Hsiehchen D, Hsieh A. Nearing saturation of cancer driver gene discovery. J Hum Genet. 2018;63:941–3.
Chen KE, Healy MD, Collins BM. Towards a molecular understanding of endosomal trafficking by retromer and retriever. Traffic. 2019;20:465–78.
Ding K, Wu S, Ying W, Pan Q, Li X, Zhao D, et al. Leveraging a multi-omics strategy for prioritizing personalized candidate mutation-driver genes: a proof-of-concept study. Sci Rep. 2015;5:17564.
Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79–90.
Caruso S, Calatayud A-L, Pilet J, La Bella T, Rekik S, Imbeaud S, et al. Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response. Gastroenterology. 2019;157:760–76.
Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC cancer gene census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18:696–705.
Kasprzak A, Adamek A. Mucins: the old, the new and the promising factors in hepatobiliary carcinogenesis. Int J Mol Sci. 2019;20:1288–30.
Babu SD, Jayanthi V, Devaraj N, Reis CA, Devaraj H. Expression profile of mucins (MUC2, MUC5AC and MUC6) in helicobacter pylori infected pre-neoplastic and neoplastic human gastric epithelium. Mol Cancer. 2006;5:1–7.
Rao CV, Asch AS, Yamada HY. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 2017;38:2–11.
Hanawalt PC, Spivak G. Transcription-coupled DNA repair: two decades of progress and surprises. Nat Rev Mol Cell Biol. 2008;9:958–70.
Nepusz T, Yu H, Paccanaro A. Detecting overlapping protein complexes in protein-protein interaction networks. Nat Methods. 2012;9:471–2.
Zaki N, Efimov D, Berengueres J. Protein complex detection using interaction reliability assessment and weighted clustering coefficient. BMC Bioinform. 2013;14:163.
Wang J, Zhong J, Chen G, Li M, Wu F-x, Pan Y. ClusterViz: a cytoscape APP for cluster analysis of biological network. IEEE/ACM Trans Comput Biol Bioinform. 2015;12:815–22.
Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects and sub- networks from complex interactome. BMC Syst Biol. 2014;8:S11.
Fuse A, Furuya N, Kakuta S, Inose A, Sato M, Koike M, et al. VPS29-VPS35 intermediate of retromer is stable and may be involved in the retromer complex assembly process. FEBS Lett. 2015;589:1430–6.
McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The ensembl variant effect predictor. Genome Biol. 2016;17:122.
Zhang J, Baran J, Cros A, Guberman JM, Haider S, Hsu J, et al. International Cancer Genome Consortium Data Portal–a one-stop shop for cancer genomics data. Database. 2011;2011:1–10.
Schulze K, Imbeaud S, eacute EL, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:1–10.
Ahn S-M, Jang SJ. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology. 2014;60:1972–82.
Zheng J, Sadot E, Vigidal JA, Klimstra DS, Balachandran VP, Kingham TP, et al. Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing. PLoS ONE. 2018;13:e0200776.
Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012;44:760–4.
Knight M, Lee S, Das GC. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene. 2000;19:3717–26.
Huang W-Y, Hsu S-D, Huang H-Y, Sun Y-M, Chou C-H, Weng S-L, et al. MethHC: a database of DNA methylation and gene expression in human cancer. Nucleic Acids Res. 2014;43:D856–D861.
Shaw RJ, Cantley LCRas. PI(3)K and mTOR signaling controls tumor cell growth. Nature. 2006;441:424–30.
Wang J, Fedoseienko A, Chen B, Burstein E, Jia D, Billadeau DD. Endosomal receptor trafficking: retromer and beyond. Traffic. 2018;19:578–90.
Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, et al. Model-guided microarray implicates the retromer complex in Alzheimer’s disease. Ann Neurol. 2005;58:909–19.
Deng H, Gao K, Jankovic J. The VPS35 gene and Parkinson’s disease. Mov Disord. 2013;28:569–75.
Temkin P, Morishita W, Goswami D, Arendt K, Chen L, Malenka R. The retromer supports AMPA receptor trafficking during LTP. Neuron. 2017;94:74–82.
McGough IJ, Steinberg F, Jia D, Barbuti PA, McMillan KJ, Heesom KJ, et al. Retromer binding to FAM21 and the WASH complex is perturbed by the parkinson disease-linked VPS35(D620N) mutation. Curr Biol. 2014;24:1670–6.
Franch-Marro X, Wendler F, Guidato S, Griffith J, Baena-Lopez A, Itasaki N, et al. Wingless secretion requires endosome-to-golgi retrieval of Wntless/Evi/Sprinter by the retromer complex. Nat Cell Biol. 2008;10:170–7.
Yang P-T, Lorenowicz MJ, Silhankova M, Coudreuse DYM, Betist MC, Korswagen HC. Wnt signaling requires retromer-dependent recycling of MIG-14/Wntless in Wnt-producing cells. Dev Cell. 2008;14:140–7.
Belenkaya TY, Wu Y, Tang X, Zhou B, Cheng L, Sharma YV, et al. The retromer complex influences Wnt secretion by recycling wntless from endosomes to the trans-golgi network. Dev Cell. 2008;14:120–31.
Farmer T, Reinecke JB, Xie S, Bahl K, Naslavsky N, Caplan S. Control of mitochondrial homeostasis by endocytic regulatory proteins. J Cell Sci. 2017;130:2359–70.
Cui Y, Carosi JM, Yang Z, Ariotti N, Kerr MC, Parton RG, et al. Retromer has a selective function in cargo sorting via endosome transport carriers. J Cell Biol. 2019;218:615–31.
Zhou M, Philips MR. Where no Ras has gone before: VPS35 steers N-Ras through the cytosol. Small GTPases. 2019;10:20–25.
Zhou M, Wiener H, Su W, Zhou Y, Liot C, Ahearn I, et al. VPS35 binds farnesylated N-Ras in the cytosol to regulate N-Ras trafficking. J Cell Biol. 2016;214:445–58.
Farmer T, O’Neill KL, Naslavsky N, Luo X, Caplan S. Retromer facilitates the localization of Bcl-xL to the mitochondrial outer membrane. Mol Biol Cell. 2019;30:1138–46.
Qiu W-H, Zhou B-S, Chu P-G, Chen W-G, Chung C, Shih J, et al. Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol. 2005;11:5266–72.
Paur J, Nika L, Maier C, Moscu-Gregor A, Kostka J, Huber D, et al. Fibroblast growth factor receptor 3 isoforms: novel therapeutic targets for hepatocellular carcinoma? Hepatology. 2015;62:1767–78.
Cho JY, Guo C, Torello M, Lunstrum GP, Iwata T, Deng C, et al. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA. 2004;101:609–14.
Haugsten EM, Sørensen V, Brech A, Olsnes S, Wesche J. Different intracellular trafficking of FGF1 endocytosed by the four homologous FGF receptors. J Cell Sci. 2005;118:3869–81.
Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, et al. Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance. Cancer Res. 2015;75:880–91.
Tang X, Feng D, Li M, Zhou J, Li X, Zhao D, et al. Transcriptomic analysis of mRNA-lncRNA-miRNA interactions in hepatocellular carcinoma. Sci Rep. 2019;9:16096.
Liang L, Song L, Yang Y, Tian L, Li X, Wu S, et al. Validation of a multi-omics strategy for prioritizing personalized candidate driver genes. Oncotarget. 2016;7:38440–50.
Gao Q, Wang K, Chen K, Liang L, Zheng Y, Zhang Y, et al. HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma. Cancer Surv. 2017;108:1328–37.
Pan Q, Long X, Song L, Zhao D, Li X, Li D, et al. Transcriptome sequencing identified hub genes for hepatocellular carcinoma by weighted-gene co-expression analysis. Oncotarget. 2016;7:38487–99.
Acknowledgements
We thank Dr. T-C He (University of Chicago, Chicago, IL) for providing the plasmids pAdEasy system, Dr. Ding Xue (School of Life Sciences, Tsinghua University) for supplying the CRISPR/Cas9 system, and Ms Yihong Sun and Ms Fang Huang for preparing the Supplementary materials.
Funding
This work was funded by the China National Natural Science Foundation (no. 81672780, KD, nos. 81872270 and 81572683, NT, and 81602417, KW), the Major National S&T program (2017ZX10202203-004 to NT), the Recruitment Program of Global Youth Experts in China (KD), the program of Artificial Intelligence in Medicine of CQ CSTC (ZHYX2019004, KD), Natural Science Foundation Project of CQ CSTC (cstc2018jcyjAX0254 to NT), the Program for Innovation Team of Higher Education in Chongqing (grant no. CXTDX201601015), the Leading Talent Program of CQ CSTC (grant no. CSTCCXLJRC201719 to NT) and Talent Development Program of CQMU for Postgraduate (grant no. BJRC201728).
Author information
Authors and Affiliations
Contributions
GZ and LL performed in vitro and in vivo experiments; XT and KD performed data analysis; WZ participated in bioinformatics analysis; YC conducted FACS analysis; YZ generated recombinant adenoviruses; DL and XL collected clinical samples; DZ performed pathological review; BH and KW participated in the discussion and design; GZ, XT, and KD wrote the manuscript with input from BH and NT; and KD and NT conceived and designed the study. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Consent for publication
All authors approved the final manuscript.
Ethics
The collection of human tumor samples and the protocols for the investigations were approved by the Institutional Review Board (IRB) in each site where the patients were recruited.
Informed consent
Written informed consent was obtained from the patients. All animal studies were conducted according to the animal protocol approved by Chongqing Medical University (2017012).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Zhang, G., Tang, X., Liang, L. et al. DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma. Oncogene 39, 3229–3244 (2020). https://doi.org/10.1038/s41388-020-1215-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-020-1215-6
This article is cited by
-
VPS35 promotes gastric cancer progression through integrin/FAK/SRC signalling-mediated IL-6/STAT3 pathway activation in a YAP-dependent manner
Oncogene (2024)
-
Molecular evolution in different subtypes of multifocal hepatocellular carcinoma
Hepatology International (2023)
-
Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma
Functional & Integrative Genomics (2023)
-
ITRAQ-based quantitative proteomic analysis reveals that VPS35 promotes the expression of MCM2-7 genes in HeLa cells
Scientific Reports (2022)
-
KLF7/VPS35 axis contributes to hepatocellular carcinoma progression through CCDC85C-activated β-catenin pathway
Cell & Bioscience (2021)